The new World Health Organization classification of lung tumours - PubMed (original) (raw)
Review
. 2001 Dec;18(6):1059-68.
doi: 10.1183/09031936.01.00275301.
Affiliations
- PMID: 11829087
- DOI: 10.1183/09031936.01.00275301
Free article
Review
The new World Health Organization classification of lung tumours
E Brambilla et al. Eur Respir J. 2001 Dec.
Free article
Abstract
Tumour classification systems provide the foundation for tumour diagnosis and patient therapy and a critical basis for epidemiological and clinical studies. This updated classification was developed with the aim to adhere to the principles of reproducibility, clinical significance, and simplicity in order to minimize the number of unclassifiable lesions. Major changes in the revised classification as compared to the previous one (WHO 1981) include the addition of two pre-invasive lesions to squamous dysplasia and carcinoma in situ; atypical adenomatous hyperplasia and diffuse idiopathic pulmonary neuroendocrine cell hyperplasia. Another change is the subclassification of adenocarcinoma: the definition of bronchioalveolar carcinoma has been restricted to noninvasive tumours. There has been substantial evolution of concepts in neuroendocrine lung tumour classification. Large cell neuroendocrine carcinoma (LCNEC) is now recognized as a histologically high grade non small cell carcinoma showing histopathological features of neuroendocrine differentiation as well as immunohistochemical neuroendocrine markers. The large cell carcinoma class has been enriched with several variants, including the LCNEC and the basaloid carcinoma, both with a dismal prognosis. Finally, a new class was defined called carcinoma with pleomorphic, sarcomatoid, or sarcomatous elements, which brings together a number of proliferations characterized by a spectrum of epithelial to mesenchymal differentiation. Immunohistochemistry and electron microscopy are invaluable techniques for diagnosis and subclassification, but our intention was to render the classification simple and practical to every surgical laboratory, so that most lung tumours could be classified by light microscopic criteria.
Similar articles
- [Classification of broncho-pulmonary cancers (WHO 1999)].
Brambilla E. Brambilla E. Rev Mal Respir. 2002 Sep;19(4):455-66. Rev Mal Respir. 2002. PMID: 12417862 Review. French. - Pathology of lung cancer.
Travis WD. Travis WD. Clin Chest Med. 2002 Mar;23(1):65-81, viii. doi: 10.1016/s0272-5231(03)00061-3. Clin Chest Med. 2002. PMID: 11901921 Review. - [New WHO classification of lung adenocarcinoma and preneoplasia].
Lantuejoul S, Rouquette I, Brambilla E, Travis WD. Lantuejoul S, et al. Ann Pathol. 2016 Jan;36(1):5-14. doi: 10.1016/j.annpat.2015.11.010. Epub 2016 Jan 11. Ann Pathol. 2016. PMID: 26791238 French. - Histological classification of lung cancer.
Maggiore C, Mulè A, Fadda G, Rossi ED, Lauriola L, Vecchio FM, Capelli A. Maggiore C, et al. Rays. 2004 Oct-Dec;29(4):353-5. Rays. 2004. PMID: 15852719 Review.
Cited by
- Preneoplasia of lung cancer.
Gazdar AF, Brambilla E. Gazdar AF, et al. Cancer Biomark. 2010;9(1-6):385-96. doi: 10.3233/CBM-2011-0166. Cancer Biomark. 2010. PMID: 22112486 Free PMC article. - Evaluating the mechanistic evidence and key data gaps in assessing the potential carcinogenicity of carbon nanotubes and nanofibers in humans.
Kuempel ED, Jaurand MC, Møller P, Morimoto Y, Kobayashi N, Pinkerton KE, Sargent LM, Vermeulen RC, Fubini B, Kane AB. Kuempel ED, et al. Crit Rev Toxicol. 2017 Jan;47(1):1-58. doi: 10.1080/10408444.2016.1206061. Epub 2016 Aug 18. Crit Rev Toxicol. 2017. PMID: 27537422 Free PMC article. Review. - High serum haptoglobin level is associated with tumor progression and predicts poor prognosis in non-small cell lung cancer.
Lu J, Wang Y, Yan M, Feng P, Yuan L, Cai Y, Xia X, Liu M, Luo J, Li L. Lu J, et al. Oncotarget. 2016 Jul 5;7(27):41758-41766. doi: 10.18632/oncotarget.9676. Oncotarget. 2016. PMID: 27248178 Free PMC article. - In vitro and in vivo antitumor activity of a novel semisynthetic derivative of cucurbitacin B.
Silva IT, Carvalho A, Lang KL, Dudek SE, Masemann D, Durán FJ, Caro MS, Rapp UR, Wixler V, Schenkel EP, Simões CM, Ludwig S. Silva IT, et al. PLoS One. 2015 Feb 12;10(2):e0117794. doi: 10.1371/journal.pone.0117794. eCollection 2015. PLoS One. 2015. PMID: 25674792 Free PMC article. - A pilot characterization of human lung NSCLC by protein pathway activation mapping.
Zupa A, Improta G, Silvestri A, Pin E, Deng J, Aieta M, Musto P, Nitti D, Mammano E, Liotta L, Belluco C, Wulfkuhle J, Petricoin E 3rd. Zupa A, et al. J Thorac Oncol. 2012 Dec;7(12):1755-1766. doi: 10.1097/JTO.0b013e3182725fc7. J Thorac Oncol. 2012. PMID: 23154546 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases